Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Study acronym: OCREFINA
StatusEnrolling by Invitation
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 31, 2025 to Jun 30, 2027
    • Trial status: Recruiting to Enrolling by Invitation
    • Site details revised
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Jun 30, 2025 to Dec 31, 2025
    • Start date changed from estimate of Oct 1, 2024 to Feb 4, 2025
    • Site details revised
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
B cell-depleting therapies, such as ocrelizumab, are among the most effective medications currently available for the treatment of multiple sclerosis (MS). This suggests that B cells play a very important role in MS. While B cells are rapidly eliminated from the blood of patients treated with medications like ocrelizumab, little is known about how effectively B cells are eliminated from lymph nodes, which are important sites of B cell activation. This study is being conducted to determine to what extent B cells are targeted in lymph nodes following ocrelizumab treatment, which may have important consequences for long-term MS outcomes.
Trial Details
NCT Number NCT06495593
Lead Sponsor University of California, San Francisco
Collaborators: Genentech, Inc.
Conditions
(from sponsor)		 Multiple Sclerosis, Relapsing-Remitting
Related terms Multiple Sclerosis, Relapsing-Remitting
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov